Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders
- PMID: 10669994
Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders
Abstract
Background: Porphyria cutanea tarda and haemochromatosis are taken to be spontaneous human models of oxidative cellular damage, with an increased risk of fibrosis and cancer evolution.
Aim: To define the relative pro-oxidant roles of porphyrin and iron, in their different molecular forms, and their effects on antioxidant biological systems.
Patients: A group of 17 patients with porphyria cutanea tarda and a group of 14 patients with primary and secondary haemochromatosis, were compared with 21 healthy controls.
Methods: Plasma retinol, tocopherol, alpha- and beta-carotene, ascorbic acid, glutathione, malonyldialdehyde and red blood cell free iron were determined using high performance liquid chromatography.
Results: Only a modest increase in iron stores was demonstrated in the porphyria cutanea tarda group; in the haemochromatosis patients ferritin levels were almost seven times higher. By contrast, there was a sharp and virtually identical increase in red blood cell free iron and malonyldialdehyde in both the patient groups. A significant reduction was observed in retinol, alpha-, beta-carotene and red blood cell glutathione levels being more marked in porphyria cutanea tarda than in haemochromatosis patients.
Conclusions: The study confirms the strong pro-oxidant effects of porphyrins in vivo, through an induction of the free toxic iron form, even though the total iron pool is not greatly expanded. The additional free-iron and porphyrin oxidant effects are documented both in red blood cell and plasma in the porphyria cutanea tarda group. It confirmed that aging exerts a negative influence in terms of pro- and antioxidant balance in all cases, but particularly in the haemochromatosis group.
Similar articles
-
Effects of vitamin E administration on the hemorheological status and redox homeostasis of patients with porphyria cutanea tarda treated with phlebotomy.Clin Hemorheol Microcirc. 2007;36(1):13-23. Clin Hemorheol Microcirc. 2007. PMID: 17211058 Clinical Trial.
-
[Significance and prevalence of the C282Y gene mutation of primary hemochromatosis in the pathogenesis of pophyria cutanea tarda].Cas Lek Cesk. 2000 Nov 22;139(23):728-30. Cas Lek Cesk. 2000. PMID: 11191743 Czech.
-
The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron.J Hepatol. 1995 Sep;23(3):259-67. J Hepatol. 1995. PMID: 8550989
-
Hemochromatosis and porphyria.Semin Gastrointest Dis. 2002 Apr;13(2):109-19. Semin Gastrointest Dis. 2002. PMID: 12064861 Review.
-
Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda--suggestions for a handling programme.Scand J Clin Lab Invest. 2000 Nov;60(7):561-79. Scand J Clin Lab Invest. 2000. PMID: 11202050 Review.
Cited by
-
Pro-oxidant and antioxidant factors in acute intermittent porphyria: family studies.J Inherit Metab Dis. 2004;27(2):251-66. doi: 10.1023/B:BOLI.0000028795.84156.da. J Inherit Metab Dis. 2004. PMID: 15159656
-
Nutrients and Porphyria: An Intriguing Crosstalk.Int J Mol Sci. 2020 May 14;21(10):3462. doi: 10.3390/ijms21103462. Int J Mol Sci. 2020. PMID: 32422947 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical